Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial

OBJECTIVES: Currently, there are no approved treatments for early disease stages of COVID-19 and few strategies to prevent disease progression after infection with SARS-CoV-2. The objective of this study is to evaluate the safety and efficacy of convalescent plasma (CP) or camostat mesylate administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Keitel, Verena, Jensen, Björn, Feldt, Torsten, Fischer, Johannes C., Bode, Johannes G., Matuschek, Christiane, Bölke, Edwin, Budach, Wilfried, Plettenberg, Christian, Scheckenbach, Kathrin, Kindgen-Milles, Detlef, Timm, Jörg, Müller, Lisa, Kolbe, Henrike, Stöhr, Andreas, Calles, Christian, Hippe, Andreas, Verde, Pablo, Spinner, Christoph D., Schneider, Jochen, Wolf, Timo, Kern, Winfried V., Nattermann, Jacob, Zoufaly, Alexander, Ohmann, Christian, Luedde, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127198/
https://www.ncbi.nlm.nih.gov/pubmed/34001215
http://dx.doi.org/10.1186/s13063-021-05181-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127198/
https://www.ncbi.nlm.nih.gov/pubmed/34001215
http://dx.doi.org/10.1186/s13063-021-05181-0

Ejemplares similares